10 research outputs found

    Strength Asymmetries in Young Elite Sailors: Windsurfing, Optimist, Laser and 420 Classes

    Get PDF
    Strength asymmetries in the upper and lower limbs may affect the body movements of the joints or limbs. Although asymmetries in the upper limbs have been studied in sailors, those in lower limbs have not been evaluated in this sport population. The aims of this study were: (i) to analyze lower limb asymmetries in young elite sailors in order to quantify the magnitude of asymmetry between limbs for variables that were established as reliable in a healthy population, and (ii) to evaluate the presence of differences between classes and sexes in inter-limb asymmetries in elite youth sailors. Sixty-eight young Spanish elite sailors (9-19 years of age) participated voluntarily in our study. Single-leg vertical countermovement jump (VCJ), single-leg horizontal countermovement jump and hand dynamometry tests were used to evaluate the strength of the upper and lower limbs. More than 50% of the sailors presented asymmetries in the lower limbs. The boys' group and Optimist class presented a greater percentage of strength asymmetry

    Performance Analysis in Olympic Sailors of the Formula Kite Class Using GPS

    Get PDF
    Formula Kite is an Olympic sport that mainly differs from other kitesurfing modalities for the use of a hydrofoil. It is considered an extreme sport due to the great technical ability required. Regarding performance, the variables that determine performance in a real competition situation have not been studied, and even less so with Olympic sailors. Therefore, the objective of this study was to determine the technical and tactical variables that differentiate elite sailors. The sample consisted of 42 Olympic sailors of the Formula Kite class, who were evaluated in three World Cups. Using a GPS device, the speed, distance traveled, maneuvers, and time spent on the courses of upwind, downwind, and beam reach were recorded. The highest-level sailors presented a higher speed in upwind/downwind/beam reach and a shorter time in upwind and beam reach. Performance seems to be more strongly influenced by technical variables, such as speed, than by tactical variables

    Performance analysis of Paralympic 2.4mR class sailing.

    No full text
    Adapted sailing is a Paralympic sport in which sailors with different types of disabilities can compete in the same event. According to 2.4mR Class, eligible impairments include limb deficiency and vision impairment. However, it is still unknown the variables that determine performance. Thus, the objectives of this study were: (i) to identify the variables that determine the sailing performance, (ii) to analyse the influence of the type of impairment on sailing performance, and (iii) analyse the influence of the wind force on sailing performance. Thirty-three elite sailors with disabilities participated and were divided into three groups according to the type of impairment: affectation of upper, lower, or upper and lower limbs. Participants were evaluated during three 2.4mR class World Cups and the following variables were assessed: velocity made good, distance and manoeuvres in upwind-downwind courses and type of impairment. Those sailors with better performance travelled a shorter distance during downwind sailing. The results showed that performance was not affected by which category the sailor was placed according to the type of impairment. The sailors with a lesser disability perform better when the wind is medium and high

    Biliary cystadenoma

    No full text
    The diagnosis of cystadenoma is rare, even more so when located in the extrahepatic bile duct. Unspecific clinical signs may lead this pathology to be misdiagnosed. The need for pathological anatomy in order to distinguish cystadenomas from simple biliary cysts is crucial. The most usual treatment nowadays is resection of the bile duct, together with cholecystectomy and Roux-en-Y reconstruction

    GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.

    No full text
    The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m2 (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However, several methodological flaws have been identified in PRODIGE 7, specially the HIPEC protocol or the choice of overall survival as the main endpoint, so its results have not been assumed as definitive, emphasizing the need for further research on HIPEC. It seems that the HIPEC protocol with high-dose mytomicin-C (35 mg/m2) is the preferred regime to evaluate in future clinical studies. GECOP-MMC is a prospective, open-label, randomized, multicenter phase IV clinical trial that aims to evaluate the effectiveness of HIPEC with high-dose mytomicin-C in preventing the development of peritoneal recurrence in patients with limited peritoneal metastasis from colon cancer (not rectal), after complete surgical cytoreduction. This study will be performed in 31 Spanish HIPEC centres, starting in March 2022. Additional international recruiting centres are under consideration. Two hundred sixteen patients with PCI ≤ 20, in which complete cytoreduction (CCS 0) has been obtained, will be randomized intraoperatively to arm 1 (with HIPEC) or arm 2 (without HIPEC). We will stratified randomization by surgical PCI (1-10; 11-15; 16-20). Patients in both arms will be treated with personalized systemic chemotherapy. Primary endpoint is peritoneal recurrence-free survival at 3 years. An ancillary study will evaluate the correlation between surgical and pathological PCI, comparing their respective prognostic values. HIPEC with high-dose mytomicin-C, in patients with limited (PCI ≤ 20) and completely resected (CCS 0) peritoneal metastases, is assumed to reduce the expected risk of peritoneal recurrence from 50 to 30% at 3 years. EudraCT number: 2019-004679-37; Clinicaltrials.gov: NCT05250648 (registration date 02/22/2022, )
    corecore